GlassScriptPhysician profile
Laura J Stitle
NPI 1457446247
$11,403.31
in general payments reported to CMS, 2019-2025
35 companies · $1,914 in 2025
The $1,914 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $1,407 · 2021: $1,641 · 2022: $1,616 · 2023: $1,841 · 2024: $1,536 · 2025: $1,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,206 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.88 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,629.82 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $1,393.24 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,059.51 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $873.87 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $727.94 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $710.21 | 2019-2025 | |
| Ucb, INC. | $684.11 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $499.59 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $481.90 | 2022-2025 | Sotyktu |
| Incyte Corporation | $467.88 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $444.06 | 2020-2025 | Nemluvio, Aklief |
| Amgen INC. | $432.21 | 2019-2024 | Otezla |
| Leo Pharma INC. | $407.44 | 2019-2025 | Adbry |
| Pfizer INC. | $341.34 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $265.35 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.65 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.66 | 2019-2020 | |
| Dermira, INC. | $101.96 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $84.33 | 2019-2020 | |
| Dermavant Sciences, INC. | $79.39 | 2022-2023 | Vtama |
| Almirall LLC | $69.66 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $59.80 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $39.52 | 2020-2021 | |
| Sandoz INC. | $37.74 | 2020-2021 | |
| Journey Medical Corporation | $35.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $26.62 | 2019 | |
| Epi Health, LLC | $21.41 | 2019 | |
| Merz North America, INC. | $19.32 | 2025 | |
| Celgene Corporation | $18.48 | 2019 | |
| Aclaris Therapeutics, INC. | $17.56 | 2019 | |
| Botanix Sb INC | $17.18 | 2025 | Sofdra |
| Biocon Biologics INC | $14.24 | 2025 | Yesintek |
| Encore Dermatology INC. | $14.07 | 2020 | |
| Lnhc, INC | $13.64 | 2025 | Zelsuvmi |
| Medline Industries LP | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Stitle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.